Review
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Jun 25, 2025; 14(2): 101693
Published online Jun 25, 2025. doi: 10.5501/wjv.v14.i2.101693
New frontiers in sickle cell disease: The role of antiviral therapies and emerging drugs in managing viral infections
Tarun Sahu, Arunita Tushar Jagzape, Meenakshi Sinha, Ramanjan Sinha, Henu Kumar Verma
Tarun Sahu, Arunita Tushar Jagzape, Meenakshi Sinha, Ramanjan Sinha, Department of Physiology, All India Institute of Medical Sciences, Raipur 492099, Chhattīsgarh, India
Henu Kumar Verma, Department of Lung Health and Immunity, Helmholtz Zentrum Munich, Munich 85764, Bayren, Germany
Author contributions: Sahu T, Jagzape AT, Sinha M, Sinha R and Verma HK were responsible for resources and data curation; Sahu T, Jagzape AT, and Verma HK were responsible for writing original draft, review and editing; Sahu T and Verma HK were responsible for methodology and validation; Sinha M, Sinha R and Verma HK were responsible for supervision; Verma HK was responsible for conceptualization; all authors read and approve the final version of manuscript for the submission.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Henu Kumar Verma, PhD, Senior Scientist, Department of Lung Health and Immunity, Helmholtz Zentrum Munich, Ingolstädter Landstraße 1, Munich 85764, Bayren, Germany. henu.verma@yahoo.com
Received: September 23, 2024
Revised: November 14, 2024
Accepted: December 3, 2024
Published online: June 25, 2025
Processing time: 272 Days and 17.5 Hours
Core Tip

Core Tip: Sickle cell disease patients are highly susceptible to viral infections due to their immune compromised state. This review highlights the complications associated with viral infections, its treatment plans, and the role of vaccinations in improving results in these patients. Future research is essential to optimize antiviral approaches in this vulnerable population.